158 results about "Carbamazepine" patented technology

A zero-order sustained-release delivery system for delivery of carbamazepine or a derivative thereof. A polymeric matrix formulation of carbamazepine comprises hydrophilic polymer or hydrophilic/hydropholic polymer mixture which permits carbamazepine or carbamezepine derivative to be released from the polymer matrix in zero-order release kinetics.

The invention provides a preparation method of ticagrelor, belonging to the technical field of medicine manufacturing. According to the method, a compound VII is taken as a raw material, and the method comprises the steps of: carrying out a nucleophilic substitution reaction on the raw material to obtain a compound VI; hydrogenating the VI, removing carbamazepine (Cbz) protection to obtain a compound V; carrying out a reaction on the V and 4, 6-dichloro-2-(allyl sulfide)-5-amio-pyrimidine to obtain a compound IV; carrying out a reaction on the IV and nitrite of alkali metal to obtain a compound III; carrying out a reaction on the III and (1R, 2S)-2-(3, 4-difluoro phenyl) cyclopropylamine to obtain a compound II; and finally, removing protecting group of the II to obtain a compound I.

This invention pertains to the formulation of small-particle suspensions of anticonvulsants and antidementia, particularly carbamazepine, for pharmaceutical use. This invention also pertains to the formulation of small-particle suspensions of immunosuppressive agents, particularly cyclosporin, for pharmaceutical use.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

The invention discloses a carbamazepine immunogen, a carbamazepine specific antibody directly obtained through the immunogen, a detection reagent containing the specific antibody and a method for detecting the content of the carbamazepine in samples to be tested. The immunodetection reagent and the detection method have the advantages that the carbamazepine immunogen is strong in specificity and high in immunogenicity; the prepared carbamazepine immunogen is strong in specificity and high in titer and has no cross reaction with 45 common drugs; the homogeneous enzyme immunodetection reagent containing the carbamazepine specific antibody can conveniently, fast and accurately determine the content of the carbamazepine in the samples and can measure a plurality of samples simultaneously on a full-automatic biochemical analyzer, so that high-throughput and fast measuring of the carbamazepine are achieved, the accuracy is high, the specificity is strong, the accuracy and the detection efficiency are greatly improved compared with the prior art, full automation in the detection process is achieved simultaneously, the requirements on detection staff is not high, and the immunodetection reagent and the detection method are easy to achieve, popularize and use.

The present invention relates to multiple-unit modified release carbamazepine compositions for oral administration which include: (i) at least one extended release unit, and (ii) at least one enteric release unit. Also provided are processes for the preparation of multiple-unit modified release compositions of carbamazepine.

The invention relates to a preparation method and an application for magnetic molecular imprinting polymers for selectively separating carbamazepine and belongs to the technical fields of environmental material preparation and pollution regulation. Nanometer ferroferric oxide modified on a surface of chitosan serves as a magnetic medium, molecular imprinting material polymerization is carried out on the surface of the nanometer ferroferric oxide by using a sediment polymerization method, and a magnetic molecular imprinting adsorption agent is obtained after template molecular carbamazepine is eluted. Obtained molecular imprinting composite materials are stable in physicochemical property, have high adsorption capacity and specific identification characteristics on the carbamazepine, have superparamagnetism, can be rapidly separated under an outside magnetic field effect, therefore, interference of a complex substrate in an actual sample is avoided, and sample treatment processes are greatly simplified. The preparation method is simple, reliable and low in cost and has a wide application prospect in analysis, detection and pollution treatment of a complex environment sample.

The invention discloses a carbamazepine immunogen, an anti-carbamazepine specific antibody, a detection reagent and a detection kit.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

The invention relates to a reagent used for detecting antigen genotypes relevant to the anaphylactic reaction of antiepileptic drugs, and a clinical application method thereof. The reagent is characterized in that: 1) the reagent comprises Taq enzyme, a chain of seven tubes and a PCR primer; 2) the PCR primer is shown in the sequence list SEQ ID No.1. The clinical application method is characterized in that: 1) four pairs of the sequence specific primers and two pairs of internal reference primers are designed by utilizing a sequence specific primer PCR-SSP according to an HLA-B sequence, and PCR amplification is carried out by taking gDNA extracted from human peripheral blood or other issues as a template; 2) gel electrophoresis is adopted for the detection so as to confirm that the genotype of the sample is HLA-B multiplied by 1502. The reagent and the method of the invention have the advantages of simple operation, high accuracy and low cost, and are especially suitable for determining that whether the antiepileptic drugs such as carbamazepine, etc. can be taken by the HLA-B multiplied by 1502 genotype detection before patients in China or Asia take antiepileptic drugs such as the carbamazepine, etc.

The invention provides a method for preparing a carbamazepine PLGA (poly lactic-co-glycolic acid) copolymer micro capsule through a supercritical fluid injection method. The method comprises the following steps: firstly dissolving carbamazepine into supercritical carbon dioxide; secondly, feeding the supercritical carbon dioxide which is dissolved with the carbamazepine into a substrate to be maintained for 1 to 5 hours through the plasticization and swelling of PLGA copolymer, and enabling the carbamazepine to be balanced in distribution between the supercritical carbon dioxide and the PLGA copolymer; finally escaping the carbon dioxide, reserving the carbamazepine in the PLGA copolymer substrate, and preparing the carbamazepine PLGA copolymer micro capsule. The carbamazepine PLGA copolymer micro capsule which is prepared through the method is high in solubility and dissolution rate.

The invention relates to the field of water treatment, and discloses a method for treating an antiepileptic drug in water by utilizing MnxCo3-xO4 nanocages for activating monoperoxysulfate; the method particularly includes the following steps: one, mixing monoperoxysulfate with an antiepileptic drug-containing aqueous solution; two, adjusting a reaction pH; three, preparing the MnxCo3-xO4 nanocages; four, adding the MnxCo3-xO4 nanocages; five, recycling the MnxCo3-xO4 nanocages, and thus completing the method for treating the antiepileptic drug in the water by utilizing the MnxCo3-xO4 nanocages for activating monoperoxysulfate. The removal effect of the typical antiepileptic drug carbamazepine in water by using the method is obvious, the removal rate reaches 95%-99%, a catalytic material can be recovered and reused through centrifugation and separation, and the cost is saved.

The invention aims to provide a carbamazepine sustained-release tablet having higher medicament release stability and higher medication security. The carbamazepine sustained-release tablet is characterized by consisting of an effectively therapeutic dose of carbamazepine and physiologically acceptable pharmaceutic adjuvant, and has the characteristics of convenient administration, lasting effect,stable curative effect, small toxic and side effect and the like.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the left stellate ganglion, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering anti-arrhythmic therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of anti-arrhythmic therapy include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenyloin, carbamazepine, valproate, and phenobarbitone.

The invention discloses a genetic testing method for risk of causing serious adverse reactions of carbamazepine. The genetic testing method comprises the following steps: collecting oral mucosa cells of a subject, extracting genome DNA (deoxyribonucleic acid) of the oral mucosa cells, testing HLA (human leukocyte antigen)-B*1502 allelotype of the genome DNA and evaluating the risk of causing the serious adverse reactions of the skin of an anti-epileptic medicament-carbamazepine, thereby providing reference basis for clinical individual medication.

The invention relates to a method for removing drugs in soil by utilizing magnetism molecular imprinting-electromagnetism grating combination. The drugs are one or more of carbamazepine, clofibric acid or diclofenac. The method comprises the following specific steps of: fully mixing preprocessed soil and a magnetism molecularly imprinted polymer, absorbing the drugs in the soil on the surface of the magnetism molecular imprinting, and separating the water soil and the magnetism molecularly imprinted polymer after reaction through an electromagnetism grid; and absorbing the magnetism molecular imprinting on the grid through a magnetic field generated by the electromagnetism grid after electrification, and effectively separating the magnetism molecular imprinting and the grid. The method provided by the invention has the advantages that the operation is simple, the effect is obvious, the arbamazepine, the clofibric acid and the diclofenac and the like in the soil are removed in one time, the drugs absorbed on the magnetism molecular imprinting are recovered and separated through the electromagnetism grid; a magnetism molecular imprinting technology is utilized to restore the soil polluted by the drugs and has the advantages that the cost is low, the restoring efficiency is high and the like; and an electromagnetism grid device is utilized to recycle the resources, so that secondary pollution is not caused.

The invention relates to the technical field of pharmaceutical chemistry, in particular to a preparation method of high-purity carbamazepine (CBZ)-valaciclovir, which comprises the steps of: suspending acyclovir into N,N-dimethylformamide, adding CBZ-L-valine and 4-dimethylamino pyridine to obtain a turbid liquid, cooling the turbid liquid to 0-10 DEG C, adding dicyclohexylcarbodiimide, preserving the temperature for 1-5h, raising the temperature to 18-30 DEG C, controlling the temperature raising time to be 1-2h, filtering solid in a reaction system after carrying out heat preservation reaction for 10-20h at a temperature of 18-30 DEG C, decompressing and concentrating filtrate to obtain an oily matter, dissolving concentrate by heating through using alcohol, cooling crystal after being dissolved and filtering, recrystallizing and filtering the obtained solid by using alcohol, dissolving the obtained solid by heating through using the N,N-dimethylformamide with matched quantity to obtain a crude solution of the CBZ-valaciclovir, adding the solution into water with a temperature of 50-80 DEG C to make the solid to separate out, filtering, washing with water with a temperature of 50-80 DEG C to obtain a filter cake, and drying to obtain the high-purity CBZ-valaciclovir.

The invention provides an HLA-B*1502 detection kit and belongs to the technical field of carbamazepine use detection. The HLA-B*1502 detection kit is characterized in that the Allele-Specific LAMP technology is used for designing specific primers aiming at the C allele of rs10484555, the relevance between the C allele of rs10484555 and HLA-B*1502 is used for judging whether a patient carries HLA-B*1502 allele or not, so that personalized carbamazepine use can be guided, and problems caused by direct testing for HLA-B*1502 are avoided. The HLA-B*1502 detection kit is low in cost, short in detecting time, high in accuracy and easy to popularize.

The invention relates to a method for extracting efficient degrading bacteria of carbamazepine, which comprises the following steps: (1) taking active sludge of a secondary sedimentation tank of an urban sewage treatment plant, inoculating the active sludge into an inorganic salt culture medium according to an inoculating volume of 5 weight percent, and acclimating the mixture by a gradient pressure type acclimation method for 2 months; and (2) standing a sample after the 2 months of the acclimation for 30 minutes, taking 1 milliliter of an upper layer water sample to perform gradient dilution, taking 1 milliliter of a bacterial solution of each diluted concentration respectively, inoculating the bacterial solution into a solid culture medium to perform enrichment culture so as to ensure that a pure single bacterial strain grows out, then inoculating the single bacterial strain into a slant culture medium, and preserving the mixture at a temperature of 4 DEG C. The method extracts the degrading bacteria of the carbamazepine from the active sludge of the secondary sedimentation tank of the urban sewage treatment plant, the strain source is easy to obtain and has a simple, convenient and quick separation and purification method and a low cost, and is environment-friendly; and the extracted strain has a degradation rate of over 75 percent to the carbamazepine, and has a good application prospect.

The invention belongs to the field of biotechnology, and particularly relates to a method for qualitatively detecting HLA-B*1502 gene with a PCR-SSP method and a clinical detection kit. The method comprises the following steps of: finding 6 specific areas capable of effectively identifying HLA-B*1502 allele type; designing 6 specific primers covering the 6 specific areas, and screening out a high-specificity primer pair applicable to PCR-SSP; and adding dUTP and UDG enzyme (uracil-DNA glycosylase) into a reaction system to solve the problem of PCR cross pollution and further improve the detection reliability. An HLA-B*1502 quick and convenient qualitative detection kit is researched and developed accordingly. The method and the clinical detection kit provided by the invention have the advantages of convenience in operation, short time, strong specificity, high accuracy, low cost and the like, and is suitable for realizing individual safe and reasonable drug use through HLA-B*1502 genotype detection before the Chinese or Asian epileptics take carbamazepine and phenytoin sodium.

The invention discloses solutions of diclofenac, carbamazepine and benzydamine, at therapeutically desirable concentrations and the solutions stable for extended periods of time at room temperature.